News|Articles|April 29, 2011
REMS Challenges Discussed
Advertisement
In late April, the Center for Business Intelligence (CBI) held a two-day forum on Drug Safety. The focus was REMS, the FDAs enforceable Risk Evaluation and Mitigation Strategy, and included discussions on REMS assessment, challenges, case studies, technology and more.
Applied Clinical Trials Editor Lisa Henderson attended the conference and blogged live. You can read the blogs by clicking the links below.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
2
ACT Brief: AI in Clinical Research, FDA Gene Therapy Approval, and High-Performing Hospital Partnerships
3
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
4
FDA Clears Itvisma as First Gene Therapy for Adolescents and Adults With SMA
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
